10.33 (-%)
As of Nov 20, 2024
Source:
Mesoblast is developing rexlemestrocel-L to fill the treatment gap for chronic heart failure (CHF). Patients with CHF continue to represent high unmet medical need despite recent advances in new therapeutic agents for chronic heart failure.
| Country | United States |
| Headquarters | melbourne |
| Phone Number | 61(3) 9639 6036 |
| Industry | manufacturing |
| CEO | Silviu Itescu |
| Website | www.mesoblast.com |